News

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...
The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.
Madrigal Pharmaceuticals’ Rezdiffra has been approved in Europe for the treatment of MASH with moderate to advanced liver ...
Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.
Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...